XENE - Xenon Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5236.89M
Enterprise Value 3162.58M
Trailing P/E N/A
Forward P/E 1-4.82
PEG Ratio (5 yr expected) 1-0.09
Price/Sales (ttm)N/A
Price/Book (mrq)3.18
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-3.66

Trading Information

Stock Price History

Beta (3Y Monthly) 1.24
52-Week Change 3-32.22%
S&P500 52-Week Change 34.18%
52 Week High 314.45
52 Week Low 35.41
50-Day Moving Average 39.23
200-Day Moving Average 39.52

Share Statistics

Avg Vol (3 month) 346.34k
Avg Vol (10 day) 321.16k
Shares Outstanding 525.78M
Float 18.02M
% Held by Insiders 13.38%
% Held by Institutions 175.58%
Shares Short (Aug 15, 2019) 4357.58k
Short Ratio (Aug 15, 2019) 47.89
Short % of Float (Aug 15, 2019) 41.44%
Short % of Shares Outstanding (Aug 15, 2019) 41.39%
Shares Short (prior month Jul 15, 2019) 4492.2k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-32.75%
Return on Equity (ttm)-66.40%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-23.63M
EBITDA -44.42M
Net Income Avi to Common (ttm)-41.59M
Diluted EPS (ttm)-1.72
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)101.8M
Total Cash Per Share (mrq)3.95
Total Debt (mrq)16.43M
Total Debt/Equity (mrq)19.84
Current Ratio (mrq)11.07
Book Value Per Share (mrq)2.91

Cash Flow Statement

Operating Cash Flow (ttm)-38.27M
Levered Free Cash Flow (ttm)-23.61M